Increased lymphoblast-like cells following umbilical cord blood stem cell transplantation do not predict recurrent acute leukemia
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TO THE EDITOR Transplantation of umbilical cord blood (UCB) stem cells is now considered by many to be as effective as that of bone marrow stem cells for children and some adults. 1, 2 We have observed that following such procedures, the marrow may show immature, lymphoblast-like cells that may cause concern for relapsed acute lymphoblastic leukemia (ALL). Here we describe 14 such cases following UCB stem cell transplant for ALL (seven) and various other malignant (six) and non-malignant (one) diseases.
During routine follow-up of a pediatric patient who had a history of precursor B lymphoblastic leukemia, serial marrow aspirate smears at 10, 10.5 and 11 months post-UCB stem cell transplant showed an increasing proportion (7%, 9% and 12%, respectively) of atypical, TdT-positive lymphoblast-like cells. Because of their morphologic resemblance to lymphoblasts, these cells gave rise to concern of relapsed leukemia. However, molecular engraftment and cytogenetic studies performed on all three specimens pointed to 100% engraftment.
To further investigate the frequency and magnitude of this phenomenon, we reviewed the hematopathology reports of all of the patients who had undergone UCB stem cell transplant at our institution between September 1992 and November 1999 to identify cases with increased lymphocytes, blasts, 'hematogone-like' cells, or 'blastlike' cells. These were compared with 79 bone marrow or peripheral blood stem cell transplant recipients, 49 of whom had a diagnosis of ALL. The pre-and post-transplant Wright-stained marrow aspirate smears were examined. Molecular engraftment studies by PCR amplification of mini-satellites, cytogenetic analysis by karyotyping and FISH, and clinical follow-up data were reviewed.
In 14 of 79 patients (17.7%) who had undergone UCB stem cell transplant for precursor B lymphoblastic leukemia (seven), biphenotypic acute leukemia (one), acute myeloblastic leukemia with maturation (two), acute myelomonocytic leukemia (one), chronic myelogenous leukemia (one), juvenile myelomonocytic leukemia (one), and Fanconi anemia (one), the post-transplant marrow specimens showed an increased proportion of immature, TdT-positive lymphoblast-like cells. Eight of the 14 patients were female, and six were male; the median age was 6.5 years (range, 1-50 years).
Differential counts of the post-UCB stem cell transplant specimens yielded a range of 1.2 to 11.7% lymphoblast-like cells (median, 3.4%). The atypical cells were recognized as early as 60 days following transplant and remained for as long as 23 months afterwards. The cells are 15-25-µm in diameter with minimal, slightly basophilic cytoplasm with occasional clear vacuolation and fine nuclear chromatin with, not uncommonly, an evident nucleolus. Figure 1 shows the spectrum of morphologic features. Of note, such cells were not seen in the peripheral blood.
In contrast, our review of the 79 patients who had undergone marrow or peripheral blood stem cell transplantation revealed only one allogeneic bone marrow transplant recipient whose marrow aspirate after transplant showed 2.2% atypical, blast-like cells. Molecular analysis of this specimen reported 100% donor engraftment.
Immunophenotyping by flow cytometry was obtained for one patient with acute myeloblastic leukemia with maturation. Analysis revealed a subpopulation (5.3% of total nucleated cells) with dim expression of CD45, of which 90% were positive for HLA-DR and 66% were positive for CD10, CD19, with strong positivity for CD34. For the remaining cases, the number of atypical cells was below the Leukemia threshold of analysis on our instrument, or, more commonly, an aliquot of the marrow was not obtained at the time of follow-up.
Molecular engraftment studies were performed on all 14 patients and demonstrated 100% donor engraftment in 12 of 14, including six of seven patients with B-ALL and one patient with biphenotypic acute leukemia. The two patients without 100% engraftment included one patient with a history of precursor B lymphoblastic leukemia who showed 97.5% engraftment at 6 months post-transplant. The other patient had undergone transplantation for CML and showed 99.3% engraftment at 3 months post-transplant. Cytogenetic studies for the patient with precursor B lymphoblastic leukemia demonstrated 100% donor engraftment by karyotype. In the case of the male patient transplanted for CML (whose donor was female), analysis by FISH showed no evidence of either the Y chromosome or the bcr-abl fusion gene.
Cytogenetic studies were performed on 10 of 14 patients and were considered to be informative with respect to engraftment status in seven patients. (In these seven patients, either the disease prior to transplant had an abnormal karyotype, or the donors and recipients were of different gender). Five of the seven patients with informative testing were within the population in which the concern for relapsed leukemia was raised. Studies on all five patients, four with B-ALL and one with biphenotypic acute leukemia, revealed 100% normal and/or donor karyotype in all five samples with atypical cells.
Nucleated and CD34-positive cell counts of the UCB stem cell products were obtained for 13 of 14 and nine of 14 patients, respectively. The median dose of infused nucleated cells was 2.6 × 10 Clinical follow-up shows 11 of 14 patients to be living without disease, including six of the seven B-ALL patients and the patient with biphenotypic leukemia (median length of follow-up (range) = 13 months (9-24)). Among the other three patients, one patient with Ph 1 -positive ALL died of relapsed ALL, despite normal cytogenetic results and 100% donor status by molecular engraftment studies 3 months earlier, when the atypical cells were noted. The patient with CML died 2 months after the atypical cells were first noted and 5 months post-UCB stem cell transplant with an EBV-positive lymphoproliferative disorder. Lastly, the patient with acute myelomonocytic leukemia died of recurrent disease 12 months after the lymphoblast-like cells were initially identified in her marrow and 15 months following UCB stem cell transplant.
In conclusion, we report the presence of lymphoblast-like cells following UCB stem cell transplant, which in our experience is seen in up to 18% of the patients and is seen as late as 2 years after transplant. While the morphologic spectrum of these cells may include hematogones, in several instances they mimic the patient's original leukemic lymphoblasts and give rise to concerns for possible relapse. In the one case in which flow cytometric analysis was feasible, the results were suggestive of hematogones. Unfortunately, complete immunophenotypic data are not available in the vast majority of the cases in the present study. Such analysis may have shed more light on the identity or lineage of the atypical cells. Increased hematogones have been well-described in the marrow of pediatric patients following treatment for malignancies involving the bone marrow.
3,4 The phenomenon we describe here appears to be quite frequent and prominent following UCB stem cell transplant and may, in fact, increase over time. Furthermore, the presence of these cells is not related to the patient's age, original disease, or the number of infused nucleated or CD34-positive cells. Our observations suggest that caution be exercised when evaluating post-UCB stem cell transplant marrow specimens, particularly those of patients transplanted for lymphoblastic leukemia. Clinical data as well as results of molecular engraftment and cytogenetic stud- 
